SHZ Basic Materials Chemicals 300233.SZ

Shandong Jincheng Pharmaceutical Group Co., Ltd

$ 12.66 0.08 %

Shandong Jincheng Pharmaceutical Group Co., Ltd., together with its affiliated companies, focuses on the global research, development, manufacturing, and distribution of Cephalosporin intermediates. The Group's extensive product line includes active pharmaceutical ingredients (APIs), biopharmaceutical products, various medical intermediates, specialty fine chemicals, and final dosage form medications. Additionally, it diversifies its operations by offering animal nutrition and healthcare products, as well as providing contract manufacturing (CMO) and contract development and manufacturing (CDMO) services. Established in 2004, the company is headquartered in Zibo, China.

CEO: Jiaquan Li - https://www.jinchengpharm.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 15.36

Loading data...

300233.SZ vs S&P500

Loading data...

No data available.

Quick ratio

1.38

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

70.33

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.18

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

1.82 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

1.55 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

6.00

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.02

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

0.79

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

95.71 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
7 indicates good financial health
Altman score
3.05 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.62 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.02 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.